Phase IIb Placebo-Controlled Double-Blind Randomized Parallel Groups Study to Determine the Efficacy and Safety of S1B-509 for Weight Loss
Latest Information Update: 05 Jun 2025
At a glance
- Drugs S1B-509 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors S1 Biopharma
Most Recent Events
- 30 May 2025 Planned End Date changed from 15 Dec 2026 to 15 Dec 2027.
- 30 May 2025 Planned primary completion date changed from 15 Dec 2025 to 15 Jun 2027.
- 30 May 2025 Planned initiation date changed from 15 Jan 2025 to 15 Oct 2025.